Literature DB >> 17873402

Common mechanisms for the regulation of B cell differentiation and transformation by the transcriptional repressor protein BCL-6.

Saritha Kusam1, Alexander Dent.   

Abstract

The BCL-6 transcriptional repressor protein is a critical regulator of normal B cell differentiation and BCL-6 has recently been shown to act as an oncogene in several mouse model systems. The molecular pathways by which BCL-6 regulates B cell differentiation and also promotes the transformation of primary B cells are undoubtedly related; however, these pathways are poorly understood. The commonly accepted model for BCL-6 function in B cells is that BCL-6 inhibits the terminal differentiation of activated B cells into plasma cells and that deregulation of BCL-6 expression leads to an inhibition of terminal differentiation and continued proliferation. BCL-6 induces a germinal-center phenotype in primary B cells by unknown mechanisms, and can reverse the terminal differentiation of plasma cell tumor lines. BCL-6 can promote the immortalization of primary B cells and can augment telomerase activity. The role of the vast majority of BCL-6 target genes and interacting proteins in normal B cell differentiation and B cell transformation is essentially unresolved and is an important area for future investigation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873402     DOI: 10.1007/bf02697368

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  46 in total

1.  Up-regulation of telomerase in human B lymphocytes occurs independently of cellular proliferation and with expression of the telomerase catalytic subunit.

Authors:  B T Hu; R A Insel
Journal:  Eur J Immunol       Date:  1999-11       Impact factor: 5.532

2.  Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas.

Authors:  Xing Wang; Zhiping Li; Akira Naganuma; B Hilda Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-29       Impact factor: 11.205

3.  Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.

Authors:  Laura Pasqualucci; Anna Migliazza; Katia Basso; Jane Houldsworth; R S K Chaganti; Riccardo Dalla-Favera
Journal:  Blood       Date:  2002-12-19       Impact factor: 22.113

4.  MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation.

Authors:  Naoyuki Fujita; David L Jaye; Cissy Geigerman; Adil Akyildiz; Myesha R Mooney; Jeremy M Boss; Paul A Wade
Journal:  Cell       Date:  2004-10-01       Impact factor: 41.582

5.  The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation.

Authors:  B H Ye; G Cattoretti; Q Shen; J Zhang; N Hawe; R de Waard; C Leung; M Nouri-Shirazi; A Orazi; R S Chaganti; P Rothman; A M Stall; P P Pandolfi; R Dalla-Favera
Journal:  Nat Genet       Date:  1997-06       Impact factor: 38.330

Review 6.  Germinal centers.

Authors:  I C MacLennan
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

7.  The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.

Authors:  Ryan T Phan; Riccardo Dalla-Favera
Journal:  Nature       Date:  2004-12-02       Impact factor: 49.962

8.  Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation.

Authors:  Chainarong Tunyaplin; A L Shaffer; Cristina D Angelin-Duclos; Xin Yu; Louis M Staudt; Kathryn L Calame
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

9.  The human BCL6 transgene promotes the development of lymphomas in the mouse.

Authors:  Beverly W Baron; John Anastasi; Anthony Montag; Dezheng Huo; Rebecca M Baron; Theodore Karrison; Michael J Thirman; Sumit K Subudhi; Robert K Chin; Dean W Felsher; Yang-Xin Fu; Timothy W McKeithan; Joseph M Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-16       Impact factor: 11.205

10.  Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma.

Authors:  B H Ye; S Chaganti; C C Chang; H Niu; P Corradini; R S Chaganti; R Dalla-Favera
Journal:  EMBO J       Date:  1995-12-15       Impact factor: 11.598

View more
  6 in total

Review 1.  Cancer biology and NuRD: a multifaceted chromatin remodelling complex.

Authors:  Anne Y Lai; Paul A Wade
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

2.  Suppression of human B cell activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin involves altered regulation of B cell lymphoma-6.

Authors:  Ashwini S Phadnis-Moghe; Robert B Crawford; Norbert E Kaminski
Journal:  Toxicol Sci       Date:  2014-12-26       Impact factor: 4.849

3.  DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas.

Authors:  Anne Y Lai; Mehrnaz Fatemi; Archana Dhasarathy; Christine Malone; Steve E Sobol; Cissy Geigerman; David L Jaye; Deepak Mav; Ruchir Shah; Leping Li; Paul A Wade
Journal:  J Exp Med       Date:  2010-08-23       Impact factor: 14.307

4.  A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity.

Authors:  Marina Cella; Anja Fuchs; William Vermi; Fabio Facchetti; Karel Otero; Jochen K M Lennerz; Jason M Doherty; Jason C Mills; Marco Colonna
Journal:  Nature       Date:  2008-11-02       Impact factor: 49.962

5.  CHD4/NuRD complex regulates complement gene expression and correlates with CD8 T cell infiltration in human hepatocellular carcinoma.

Authors:  Simin Shao; Haowei Cao; Zhongkun Wang; Dongmei Zhou; Chaoshen Wu; Shu Wang; Dian Xia; Daoyong Zhang
Journal:  Clin Epigenetics       Date:  2020-02-18       Impact factor: 6.551

6.  IgA and Differentiation-associated Transcription Factors in Chronic Otitis Media with Effusion.

Authors:  Il Ho Shin; Ok Young Shin; Sung-Ho Cha; Young Il Kim; Jin Woo Lee; Seung Geun Yeo
Journal:  Clin Exp Otorhinolaryngol       Date:  2009-09-23       Impact factor: 3.372

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.